Stable expression of shRNA for the control of recombinant adenovirus replication

Autor(es)

Lana, M. V. G. ; Antunes, F. ; Tessarollo, N. G. ; Strauss, B. E.

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Medical and Biological Research; v. 56, p. 8-pg., 2023-01-01.

Resumo

Preventing the replication of adenovirus could have practical uses, such as controlling infection with wild-type virus or in applications involving recombinant vectors. Mainly transient methods have been used to inhibit adenovirus replication, including siRNA or drugs. Here, we tested whether stable expression of shRNA designed to target hexon, Iva2, or pol can inhibit the replication of a recombinant adenoviral vector, Ad-LacZ (serotype 5, E1/E3 deleted), in 293T cells. Significant knockdown correlating with reduced Ad-LacZ replication was achieved only when hexon was targeted. Cell sorting and isolation of cellular clones further accentuated knockdown of the hexon transcript, reduced protein levels by more than 90%, and diminished adenovirus production. As visualized by transmission electron microscopy, the cellular clone expressing the hexon-specific shRNA yielded 89.2% fewer particles compared to the parental 293T cells. Full scale production followed by purification revealed a 90.2% reduction in Ad-LacZ biological titer. These results support the notion that stable expression of shRNA can be used as a means to control adenovirus replication. (AU)

• Processo FAPESP: 18/04800-5 - O papel das isoformas de p73 na modulação da resposta de células B16F10 transduzidas com vetores adenovirais portadores dos cDNAs para p19Arf e IFNbeta
• Beneficiário: Fernanda Antunes
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/25290-2 - O estudo do papel dos neoantígenos na modulação da resposta anti-tumoral promovido pelo tratamento com p19Arf e IFN-beta em células B16
• Beneficiário: Nayara Gusmão Tessarollo
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 12/05066-7 - Utilização de shRNA anti-hexon e anti-IVa2 durante a produção de vírus adeno-associado como estratégia de eliminar adenovírus helper: Prova de princípio
• Beneficiário: Marlous Vinícius Gomes Lana
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 15/26580-9 - Terapia gênica do câncer: alinhamento estratégico para estudos translacionais
• Beneficiário: Bryan Eric Strauss
• Modalidade de apoio: Auxílio à Pesquisa - Temático